Promise Of A New Day For Rx-To-OTC Switch Ruled 2012 In “The Tan Sheet”
This article was originally published in The Tan Sheet
The most popular stories in “The Tan Sheet” during 2012 dealt with FDA’s nonprescription safe use regulatory extension initiative, as well as planned switches by Pfizer and Merck. In dietary supplements, coverage of firms struggling with GMPs and congressional threats to DSHEA drew the most interest.
You may also be interested in...
Many monograph OTCs are overshadowed in the marketplace by NDA products and have much less space on store shelves. With some NDA-approved ingredients moved to monographs, FDA pre-market approval would no longer be required and more firms could make those products.
Supplement industry stakeholders see deaths reported in energy drinks AERs as a potential rallying point for Capitol Hill to consider tightening oversight of the industry. Senators Durbin and Blumenthal question FDA’s investigation of the deaths and ask for more action by the agency.
Reckitt Benckiser went high with its $1.4 billion bid for Schiff Nutrition, though the acquisition’s impressive multiples are not entirely out of line with earlier deals in the nutrition space. Analyst Damian Witkowski notes that Airborne, MegaRed and other Schiff brands already are primed for organic growth.